Hepatitis C virus and glucose and lipid metabolism (Q37386098)

20 August 2017

1 reference

title

Hepatitis C virus and glucose and lipid metabolism (English)

1 reference

20 August 2017

0 references

1 reference

M Alaei

1

1 reference

PubMed ID

19195632

20 August 2017

F Negro

series ordinal

2

1 reference

20 August 2017

1 December 2008

1 reference

20 August 2017

Diabetes and Metabolism

1 reference

20 August 2017

34

1 reference

20 August 2017

6 Pt 2

1 reference

20 August 2017

692-700

1 reference

Review article: chronic hepatitis C--natural history and cofactors

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

STEATOSIS IN CHRONIC HEPATITIS C: WHY DOES IT REALLY MATTER?

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Host- and disease-specific factors affecting steatosis in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Mechanisms and significance of liver steatosis in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Nonlinear partial differential equations and applications: Genomic analysis of the host response to hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Replication of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Essential Role of Domain III of Nonstructural Protein 5A for Hepatitis C Virus Infectious Particle Assembly

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis affects chronic hepatitis C progression in a genotype specific way

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance: a metabolic pathway to chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus infection and incident type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Higher incidence of diabetes in liver transplant recipients with hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus infection and post-transplant diabetes mellitus among renal transplant patients: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Prevalence and clinical spectrum of chronic viral hepatitis in a middle-aged Swedish general urban population

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Correlation between insulin resistance and hepatitis C viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

TNF-{alpha}, chronic hepatitis C and diabetes: a novel triad

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Fibrogenic impact of high serum glucose in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Weighty issues in hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Signaling by type I and II cytokine receptors: ten years after

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

Obesity and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2808%2974606-8

7 January 2021

10.1016/S1262-3636(08)74606-8

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19195632